Evgen Pharma

Clinical-stage drug development company focused on cancer and neurological diseases, headquartered at Alderley Park, Cheshire, UK. Core technology: Sulforadex®, a synthetic and stabilised version of naturally occurring sulforaphane. Lead candidate SFX-01 is in development for metastatic breast cancer, with objective responses in Phase 2a. Also exploring glioblastoma and autism spectrum disorder applications.